Table 2.
Unadjusted and adjusted associations between 30% decrease in ctDNA at 4 weeks and clinical outcomes.
| Outcome | Unadjusted (univariate) | Adjusted (multivariate)1 | ||
|---|---|---|---|---|
| OR/HR2 (95% CI) | P-value | OR/HR2 95% CI | P-value | |
| Partial response | -3 | - | -3 | - |
| Clinical benefit | OR = 6.321 (2.256, 17.717) | 0.0005 | OR = 6.912 (2.304, 20.732) | 0.0006 |
| Progression-free survival | HR = 0.277 (0.161, 0.479) | <0.0001 | HR = 0.324 (0.183, 0.571) | 0.0001 |
1
Adjusted for diagnosis, treatment type, and number of prior lines of therapy
2
Odd ratios (ORs)/hazard ratios (HRs) represent odds/risk of outcome for decrease ≥ 30% in week 4 ctDNA compared to change > −30%
3
Cannot be estimated because all patients with PR had ≥ 30% decrease in week 4 ctDNA